Loading...
•
Dec 31, 2024
Celcuity Q4 2024 Earnings Report
Celcuity reported increased operating expenses and a higher net loss in Q4 2024 compared to the prior year.
Key Takeaways
Celcuity's fourth quarter results reflected a significant rise in R&D and administrative expenses, contributing to a wider net loss. However, the company ended the quarter with a strong cash position to support ongoing clinical development programs.
Q4 2024 net loss widened to $36.7 million compared to $18.8 million in Q4 2023.
Non-GAAP adjusted net loss was $32.3 million, or $0.75 per share.
R&D expenses rose substantially due to trial-related costs and staffing.
Cash, cash equivalents and short-term investments totaled $235.1 million, expected to fund operations through 2026.
Celcuity
Celcuity
Forward Guidance
Celcuity plans multiple clinical trial data releases in 2025, including topline data from the PIK3CA wild-type cohort and initial prostate cancer trial results.
Positive Outlook
- Topline data from VIKTORIA-1 PIK3CA wild-type cohort expected in Q2 2025
- Topline data from Phase 1b/2 prostate cancer trial expected in late Q2 2025
- PIK3CA mutant-type cohort data expected in Q4 2025
- First patient enrollment for VIKTORIA-2 Phase 3 on track for Q2 2025
- Strong cash position projected to fund operations through 2026
Challenges Ahead
- High cash burn rate with $27.8 million used in operations in Q4
- Increased R&D expenses driven by multiple concurrent trials
- G&A expenses nearly doubled year-over-year in Q4
- Ongoing net losses with no revenue reported
- Continued dependence on trial outcomes for future progress